[go: up one dir, main page]

MX2016000651A - Metodo para la parada, proteccion y conservacion de organos y reduccion de la lesion tisular. - Google Patents

Metodo para la parada, proteccion y conservacion de organos y reduccion de la lesion tisular.

Info

Publication number
MX2016000651A
MX2016000651A MX2016000651A MX2016000651A MX2016000651A MX 2016000651 A MX2016000651 A MX 2016000651A MX 2016000651 A MX2016000651 A MX 2016000651A MX 2016000651 A MX2016000651 A MX 2016000651A MX 2016000651 A MX2016000651 A MX 2016000651A
Authority
MX
Mexico
Prior art keywords
organs
injury
reduction
subject
conservation
Prior art date
Application number
MX2016000651A
Other languages
English (en)
Inventor
Dobson Geoffrey
Original Assignee
Hibernation Therapeutics A Kf Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013902657A external-priority patent/AU2013902657A0/en
Application filed by Hibernation Therapeutics A Kf Llc filed Critical Hibernation Therapeutics A Kf Llc
Publication of MX2016000651A publication Critical patent/MX2016000651A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención se refiere a composiciones y a métodos de inducción de la parada de órganos, mantenimiento de la parada y reanimación en un sujeto que ha padecido una enfermedad o lesión potencialmente mortal; preparación, extracción y conservación de órganos, tejidos y células; reducción de efectos perjudiciales de al menos uno de anestesia, cirugía, intervención clínica y derivación cardiopulmonar en la lesión de tejidos, órganos y células de un sujeto; o reducción de los efectos perjudiciales de la cirugía o intervención clínica en la lesión de órganos y cerebro en todo el organismo de un sujeto. La composición comprende (i) un compuesto seleccionado de al menos uno de un agente de apertura del canal de potasio, un agonista del canal de potasio y un agonista del receptor de adenosina; (ii) un agente antiarrítmico o un anestésico local; y (iii) citrato.
MX2016000651A 2013-07-17 2014-07-17 Metodo para la parada, proteccion y conservacion de organos y reduccion de la lesion tisular. MX2016000651A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AU2013902657A AU2013902657A0 (en) 2013-07-17 A method for reducing infection, sepsis and injury
AU2013902658A AU2013902658A0 (en) 2013-07-17 A method for reducing inflammation, coagulation and adhesions
AU2013902656A AU2013902656A0 (en) 2013-07-17 A method for inducing whole body arrest
AU2013902659A AU2013902659A0 (en) 2013-07-17 A method for treating haemorrhage, shock and brain injury
AU2013903644A AU2013903644A0 (en) 2013-09-23 A method for organ arrest, protection and preservation and reducing tissue injury
PCT/AU2014/050132 WO2015006830A1 (en) 2013-07-17 2014-07-17 A method for organ arrest, protection and preservation and reducing tissue injury

Publications (1)

Publication Number Publication Date
MX2016000651A true MX2016000651A (es) 2016-10-14

Family

ID=52345629

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016000651A MX2016000651A (es) 2013-07-17 2014-07-17 Metodo para la parada, proteccion y conservacion de organos y reduccion de la lesion tisular.
MX2016000649A MX2016000649A (es) 2013-07-17 2014-07-17 Un metodo para tratar la infeccion, sepsis y lesion.
MX2016000650A MX2016000650A (es) 2013-07-17 2014-07-17 Un metodo para tratar la hemorragia, choque y lesion cerebral.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016000649A MX2016000649A (es) 2013-07-17 2014-07-17 Un metodo para tratar la infeccion, sepsis y lesion.
MX2016000650A MX2016000650A (es) 2013-07-17 2014-07-17 Un metodo para tratar la hemorragia, choque y lesion cerebral.

Country Status (8)

Country Link
US (3) US20160166598A1 (es)
EP (3) EP3021855A4 (es)
CN (3) CN105705151A (es)
AU (3) AU2014292826A1 (es)
BR (3) BR112016000809A2 (es)
CA (3) CA2917629A1 (es)
MX (3) MX2016000651A (es)
WO (5) WO2015006831A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560722A2 (en) 2010-04-21 2013-02-27 The Regents of the University of Michigan Fluoroscopy-independent, endovascular aortic occlusion system
US9474882B2 (en) 2013-02-26 2016-10-25 Prytime Medical Devices, Inc. Fluoroscopy-independent balloon guided occlusion catheter and methods
WO2015035393A1 (en) 2013-09-09 2015-03-12 Pryor Medical Devices, Inc. Low-profile occlusion catheter
US10232142B2 (en) 2014-06-10 2019-03-19 Prytime Medical Devices, Inc. Conduit guiding tip
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
AU2016232781B2 (en) 2015-03-19 2017-11-02 Prytime Medical Devices, Inc. System for low-profile occlusion balloon catheter
EP3371212B1 (en) * 2015-11-06 2023-10-11 The Board of Trustees of the University of Illinois Peptides and method for treatment of cardiac arrest
WO2017137528A1 (en) * 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus
EP4302815A3 (en) 2016-06-02 2024-03-27 Prytime Medical Devices, Inc. System and method for low-profile occlusion ballon catheter
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
WO2018132623A1 (en) 2017-01-12 2018-07-19 The Regents Of The University Of California Endovascular perfusion augmentation for critical care
JP7660806B2 (ja) 2017-04-21 2025-04-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 大動脈の部分遮断用の大動脈血流量計およびポンプ
EP4233989B1 (en) 2017-06-07 2026-01-14 Supira Medical, Inc. Intravascular fluid movement devices, systems, and methods of use
CN111556763B (zh) 2017-11-13 2023-09-01 施菲姆德控股有限责任公司 血管内流体运动装置、系统
WO2019145748A2 (en) * 2017-12-05 2019-08-01 Neuroindex Ltd. Systems and methods for anesthesia management
CN112004563B (zh) 2018-02-01 2024-08-06 施菲姆德控股有限责任公司 血管内血泵以及使用和制造方法
US20190262617A1 (en) 2018-02-23 2019-08-29 Medtronic, Inc. Generation of diagnostic metrics for use in determining delivery of pacing therapy by a cardiac pacing device
CN108753683B (zh) * 2018-05-26 2022-02-15 温州医科大学 一种促进冻存组织器官和细胞活性复苏的溶液体系
US12097345B2 (en) 2018-06-01 2024-09-24 Penumbra, Inc. Infusion catheter and methods of use
US12161857B2 (en) 2018-07-31 2024-12-10 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
CA3107489A1 (en) 2018-08-06 2020-02-13 Prytime Medical Devices, Inc. System and method for low profile occlusion balloon catheter
WO2020047539A1 (en) * 2018-08-31 2020-03-05 Louisiana Tech Research Corporation System and method for network analysis of a patient's neuro-cardio-respiratory system
EP3860675A4 (en) 2018-10-05 2022-07-13 Shifamed Holdings, LLC INTRAVASCULAR BLOOD PUMPS AND METHODS OF USE
CN110352951A (zh) * 2018-11-15 2019-10-22 崔磊 一种无血清无dmso组织工程骨冻存液及其制备和冻存方法
CN109248173A (zh) * 2018-11-23 2019-01-22 浙江省人民医院 一种心脏停搏液
WO2020122928A1 (en) * 2018-12-14 2020-06-18 National Taiwan University A stable cardioplegic solution for cardiac surgery
ES3019584T3 (en) 2019-01-10 2025-05-20 Xvivo Holding B V An apparatus and a method for ex-vivo measurement of performance of a donor heart
US12350289B2 (en) 2019-03-29 2025-07-08 Virginia Commonwealth University Polymer agents for cardiopulmonary resuscitation
CN110057821B (zh) * 2019-04-16 2021-09-07 上海交通大学 用于人类配子快速冻融过程观测的低温显微成像系统
WO2020223462A1 (en) * 2019-04-30 2020-11-05 University Of Florida Research Foundation, Inc. Biomarker panel for sepsis encephalopathy
EP3996797A4 (en) 2019-07-12 2023-08-02 Shifamed Holdings, LLC INTRAVASCULAR BLOOD PUMPS AND METHOD OF USE AND METHOD OF MAKING
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
EP4010046A4 (en) 2019-08-07 2023-08-30 Calomeni, Michael Catheter blood pumps and collapsible pump housings
US20220322656A1 (en) * 2019-08-28 2022-10-13 The Regents Of The University Of Michigan Preservation of organs for transplant and non-transplant surgeries
US20220313144A1 (en) * 2019-09-12 2022-10-06 The General Hospital Corporation System amd method for determining treatment outcomes for neurological disorders based on functional connectivity parameters
JP2022549325A (ja) * 2019-09-24 2022-11-24 ピナンブラ、インク 注入カテーテルとその使用方法
WO2021062260A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible blood conduits
WO2021062270A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible pump housings
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof
CN110692580B (zh) * 2019-11-15 2021-11-02 苑春亭 一种刺参度夏池塘及安全通过夏眠的方法
EP4072650A4 (en) 2019-12-11 2024-01-10 Shifamed Holdings, LLC Descending aorta and vena cava blood pumps
CN113134116B (zh) * 2020-01-20 2022-09-06 山东威高宏瑞医学科技有限公司 内镜微创手术用的填充组合物及填充制剂
KR102332569B1 (ko) * 2020-03-05 2022-01-04 서울대학교병원 심정지 후 예후에 관한 정보를 제공하기 위한 방법, 시스템 및 비일시성의 컴퓨터 판독 가능한 기록 매체
AU2021239935A1 (en) 2020-03-16 2022-10-06 Certus Critical Care, Inc. Blood flow control devices, systems, and methods and error detection thereof
CN111407244A (zh) * 2020-03-30 2020-07-14 上海大学 基于svr算法的左心室收缩末期弹性预测方法及系统
CN111345293B (zh) * 2020-04-08 2021-08-27 江门海关技术中心 一种虫类标本用防蛀剂及其制备方法
CN111937861B (zh) * 2020-08-17 2021-10-26 南昌大学第二附属医院 一种七氟烷缺血再灌注装置及使用方法
CN112195151B (zh) * 2020-10-28 2022-06-21 范德里希(上海)生物科技有限公司 一种牙髓间充质干细胞复苏培养液、制备方法及复苏培养方法
CN112826463B (zh) * 2020-12-31 2023-11-10 苏州爱琴生物医疗电子有限公司 一种血压调控范围的确定装置和相关设备
EP4307994A4 (en) * 2021-03-18 2025-03-26 Washington University Hemodilution detector
WO2022197895A1 (en) 2021-03-18 2022-09-22 Prytime Medical Devices, Inc. Vascular occlusion catheter
CN113854280B (zh) * 2021-09-06 2022-05-31 创芯国际生物科技(广州)有限公司 一种低温保存液及其制备方法和应用
WO2023154844A2 (en) * 2022-02-10 2023-08-17 Workman David Henry Compositions comprising nad+ and associated methods of treatment
US12405820B2 (en) 2022-03-30 2025-09-02 International Business Machines Corporation Central randomized scheduler for hypothesis-based workloads
US20230404066A1 (en) * 2022-06-15 2023-12-21 Vascular Perfusion Solutions, Inc. Tissue perfusion and viability sensing system
WO2024050139A1 (en) * 2022-09-02 2024-03-07 AnaBios Corporation Therapeutic uses of cardiac myosin inhibitors
CN117731312A (zh) 2022-09-13 2024-03-22 上海联影医疗科技股份有限公司 一种医学图像的扫描方法和系统
WO2024206920A2 (en) * 2023-03-31 2024-10-03 Ntt Research, Inc. Monitoring cardiac contractility during cardiac treatments
CN116491497B (zh) * 2023-04-26 2025-05-27 复旦大学附属中山医院 一种应用于消化内镜体外模拟手术的猪消化道保存液
WO2025155695A1 (en) * 2024-01-18 2025-07-24 The Johns Hopkins University Intraoperative monitor of aggregate organ injury time

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3795581A (en) * 1971-11-01 1974-03-05 American Hospital Supply Corp Method of maintaining or restoring the 2,3-diphosphoglycerate content of human red cells
US4112070A (en) * 1977-06-08 1978-09-05 Research Corporation Blood preservation system
SU878297A1 (ru) 1978-05-03 1981-11-07 Научно-Исследовательский Институт Трансплантологии И Искусственных Органов Состав дл сохранени жизнеспособности оперируемого сердца
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5006512A (en) 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
US4968675A (en) * 1988-10-28 1990-11-06 Upjohn Non-hemolytic lazaroid parenteral formulation
US5256770A (en) 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
DE3926287A1 (de) 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5145771A (en) 1990-04-12 1992-09-08 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
RU2025973C1 (ru) 1992-02-10 1995-01-09 Научно-производственное предприятие "Биофарм" Раствор для консервации живых органов
US5370989A (en) 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
CN1151685A (zh) * 1994-05-25 1997-06-11 杰丽·I·雅各布森 改善衰老过程的方法和设备
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
US5554497A (en) 1994-12-12 1996-09-10 Charlotte-Mecklenburg Hospital Authority Cardioplegic solution for arresting an organ
US5656420A (en) 1995-02-24 1997-08-12 University Of Kentucky Research Foundation Method for employing the delta opioid dadle to extend tissue survival time during ischemia
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
JP3875295B2 (ja) 1995-11-30 2007-01-31 功 竹内 心筋保護液
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
US6043224A (en) 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
IT1297886B1 (it) 1997-02-28 1999-12-20 Carmine Antropoli Nifedipina per uso topico
JP2002505687A (ja) 1997-06-18 2002-02-19 ディスカバリー セラピューティクス，インコーポレイテッド 脈管再生手順の後の再狭窄を防止するための組成物および方法
CN1057192C (zh) 1997-09-10 2000-10-11 上海长征医院 一种配制多器官保存液的方法
US6011017A (en) 1998-04-15 2000-01-04 Cypros Pharmaceutical Corp. Method of reducing pulmonary hypertension and atrial fibrillation after surgery using cardiopulmonary bypass
WO2000003716A1 (en) 1998-07-16 2000-01-27 Memorial Sloan-Kettering Cancer Center Topical compositions comprising an opioid analgesic and an nmda antagonist
IL136583A0 (en) 1998-10-23 2001-06-14 Polyheal Ltd Compositions of microspheres for wound healing
US6358208B1 (en) 1998-11-21 2002-03-19 Philipp Lang Assessment of cardiovascular performance using ultrasound methods and devices that interrogate interstitial fluid
DE60034778T2 (de) 1999-03-23 2008-01-31 Hibernation Therapeutics Ltd., Townsville Stoppen, schützen und konservieren von organen
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
WO2001054679A2 (en) 2000-01-27 2001-08-02 Children's Hospital Research Foundation Transdermal composition containing an anesthetic and a vasodilator agent
JP2001261575A (ja) 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
US6569615B1 (en) 2000-04-10 2003-05-27 The United States Of America As Represented By The Department Of Veteran's Affairs Composition and methods for tissue preservation
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
WO2001082914A2 (en) 2000-04-28 2001-11-08 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
WO2002026140A1 (en) 2000-09-26 2002-04-04 Medtronic, Inc. Medical method and system for directing blood flow
JP2005532260A (ja) 2002-01-29 2005-10-27 コグネティックス・インコーポレイテッド 器官保護剤としてのカッパ−ｐｖｉｉａ−関連コノトキシン
CA2379211A1 (fr) * 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
ATE418991T1 (de) 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US20040229780A1 (en) 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
US6921633B2 (en) 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
US20040167226A1 (en) 2002-12-16 2004-08-26 Serafini Tito A. Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
US20060034941A1 (en) 2002-12-23 2006-02-16 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
US6992075B2 (en) 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
EP1628649A4 (en) 2003-06-02 2010-06-02 Samaritan Pharmaceuticals Inc NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS
US7049309B2 (en) 2003-10-14 2006-05-23 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one potassium channel modulators
EP1827298A4 (en) 2004-12-22 2011-09-28 Univ Emory THERAPEUTIC APPARATUS FOR IMPROVING THE PROTECTIVE EFFECTS OF POST-CONDITIONING ORGANS
WO2007030198A2 (en) 2005-07-11 2007-03-15 Human Biosystems Improved methods and solutions for storing donor organs
CN101500409A (zh) * 2006-05-29 2009-08-05 低温药理有限公司 改善的组织维持
US20090258092A1 (en) 2006-05-29 2009-10-15 Hibernation Threapeutics Limited Improved Tissue Maintenance
US20130122108A1 (en) * 2006-06-06 2013-05-16 Robert G Matheny Compositions for Regenerating Defective or Absent Myocardium
CN103495173B (zh) * 2006-07-25 2016-11-23 低温药理Kf有限公司 创伤治疗
EP2073790B1 (en) * 2006-10-06 2018-05-16 NewSouth Innovations Pty Limited Particle formation
US20100119554A1 (en) * 2007-03-02 2010-05-13 Hibernation Therapeutics Limited Transplants
CN100423638C (zh) 2007-03-22 2008-10-08 南京吉脉生物技术有限公司 一种器官保存液及其制备方法
SG185322A1 (en) * 2007-07-25 2012-11-29 Hibernation Therapeutics Ltd Improved organ protection, preservation and recovery
CN101496512A (zh) * 2008-02-01 2009-08-05 扬子江药业集团上海海尼药业有限公司 一种器官保存液及其制备方法
US20090198145A1 (en) * 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
WO2011075391A1 (en) 2009-12-15 2011-06-23 Schering Corporation Formulations of acadesine
CN102726366B (zh) 2011-04-07 2014-06-04 中国人民解放军第二军医大学 一种器官保存液及其配制方法

Also Published As

Publication number Publication date
BR112016000898A2 (pt) 2017-08-22
US20160271161A1 (en) 2016-09-22
EP3021854A4 (en) 2017-03-29
EP3021854A1 (en) 2016-05-25
CA2917645C (en) 2022-06-21
CN105579045A (zh) 2016-05-11
CN105722516A (zh) 2016-06-29
WO2015006828A9 (en) 2015-03-12
EP3021856A1 (en) 2016-05-25
EP3021856A4 (en) 2017-03-29
AU2014292825A1 (en) 2016-02-04
BR112016000804A2 (pt) 2017-08-22
MX2016000650A (es) 2016-11-30
AU2014292826A1 (en) 2016-02-04
WO2015006829A1 (en) 2015-01-22
US20160158280A1 (en) 2016-06-09
US20160166598A1 (en) 2016-06-16
AU2014292827A9 (en) 2016-03-10
CN105705151A (zh) 2016-06-22
WO2015006831A9 (en) 2015-03-26
AU2014292827A1 (en) 2016-02-04
WO2015006827A1 (en) 2015-01-22
BR112016000809A2 (pt) 2017-08-22
WO2015006830A9 (en) 2016-01-28
WO2015006831A1 (en) 2015-01-22
WO2015006830A1 (en) 2015-01-22
CA2917629A1 (en) 2015-01-22
CA2917645A1 (en) 2015-01-22
US10786525B2 (en) 2020-09-29
EP3021855A1 (en) 2016-05-25
MX2016000649A (es) 2016-11-30
WO2015006828A1 (en) 2015-01-22
EP3021856B1 (en) 2020-10-07
EP3021855A4 (en) 2017-03-29
CA2917653A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
MX2016000651A (es) Metodo para la parada, proteccion y conservacion de organos y reduccion de la lesion tisular.
CL2020002737A1 (es) Métodos para expandir linfocitos infiltrantes de tumores (divisional de la solicitud no. 201902769)
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112017005044A2 (pt) composições compreendendo uma ou mais cepas microbianas, célula vegetal tendo um revestimento, método para produzir um consórcio microbiano, consórcio microbiano, método para melhorar a saúde, o crescimento ou a produtividade de uma planta
MX373187B (es) Terapia de combinación para tratar cáncer.
CO6630147A2 (es) Modificador del sabor dulce
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
CU23880B1 (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
ZA202110111B (en) Methods and compositions for treating liver disorders
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
ECSP12012217A (es) Combinación Farmaceutica para el tratamiento del dolor
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
MX2022009736A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
BR112015024621A8 (pt) usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
MX2018005625A (es) Metodo para tratar enfermedades mediante anestesia auricular de los nervios craneales.
PH12015500226B1 (en) Compositions and methods for the treatment of bone voids and open fractures
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
MX2018001965A (es) Formulaciones liquidas que contienen picosulfato y citrato de magnesio.
MX378586B (es) Composición y método para el tratamiento de padecimientos de la piel
MX2015017555A (es) Metodos y composiciones para aumentar la movilizacion de las celulas madre.
MX381102B (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
BR112015023254A2 (pt) composições concentradas sólidas contendo zinco piritiona
BR112016029996A2 (pt) utilização cosmética, composição e método cosmético para tratar os odores corporais
BR112016002643A8 (pt) composições para tratamento de pele e método para produção de uma composição para tratamento de pele